Solid Biosciences Inc

Research Solid Biosciences Inc (SLDB) on Bullrun: market cap USD 932.32M. Explore financials, valuation history, model signals, and stock context.

Key Metrics

• TickerSLDB
• ExchangeNASDAQ
• CountryUnited States
• SectorHealthcare
• IndustryBiotechnology
• CurrencyUSD
• Market capUSD 932.32M
• Financial periodFY2025
• Net income-USD 174.33M
• Free cash flow-USD 157.44M

Valuation Snapshot

latest market cap is USD 932.32M.

About Solid Biosciences Inc

Solid Biosciences Inc. develops therapies for neuromuscular and cardiac diseases in the United States. The company's lead product candidate is SGT-003, which is in phase 1/2 for the treatment of Duchenne muscular dystrophy. It develops SGT-212 for the treatment of Friedreich's ataxia that is in phase 1b clinical trial; SGT-501 for the treatment of catecholaminergic polymorphic ventricular tachycardia that is in preclinical phase;

Frequently asked questions

What is Solid Biosciences Inc's market cap?

Solid Biosciences Inc's market capitalization is USD 932.32M.

What does Solid Biosciences Inc do?

Solid Biosciences Inc. develops therapies for neuromuscular and cardiac diseases in the United States. The company's lead product candidate is SGT-003, which is in phase 1/2 for the treatment of Duchenne muscular dystrophy.